AZD2014, an inhibitor of mTORC1 and mTORC2, is highly effective in ER+ breast cancer when administered using intermittent or continuous schedules

Molecular Cancer Therapeutics

Volumn 14, Issue 11, 2015, Pages 2508-2518

  Guichard, Sylvie M ^a   Curwen, Jon ^a   Bihani, Teeru ^a,c   D'Cruz, Celina M ^a   Yates, James W T ^a   Grondine, Michael ^a   Howard, Zoe ^b   Davies, Barry R ^a   Bigley, Graham ^a   Klinowska, Teresa ^a   Pike, Kurt G ^a   Pass, Martin ^a   Chresta, Christine M ^a   Polanska, Urszula M ^a   McEwen, Robert ^a   Delpuech, Oona ^a   Green, Stephen ^a   Cosulich, Sabina C ^a  

^a ASTRAZENECA   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Radius Health Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; FULVESTRANT; PROTEIN KINASE B; TAMOXIFEN; VISTUSERTIB; ANTINEOPLASTIC AGENT; ESTRADIOL; ESTROGEN RECEPTOR; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MORPHOLINE DERIVATIVE; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER REGRESSION; CELL COUNT; CELL DEATH; CELL PROLIFERATION; COMPETITIVE BINDING ASSAY; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA DAMAGE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; ENZYME PHOSPHORYLATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MCF 7 CELL LINE; MOUSE; NONHUMAN; ORAL CLEARANCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR REGRESSION; TUMOR XENOGRAFT; VOLUME OF DISTRIBUTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMISTRY; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG SCREENING; HEK293 CELL LINE; IMMUNOBLOTTING; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; FEMALE; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; MCF-7 CELLS; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MORPHOLINES; MULTIPROTEIN COMPLEXES; PROTEIN KINASE INHIBITORS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958231284     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0365     Document Type: Article

References (32)

1. Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci 2015;2: 124-35.
2. Xu K, Liu P, Wei W. mTOR signaling in tumorigenesis. Biochim Biophys Acta 2014;1846:638-54.
3. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 2015;15:7-24.
4. Martini M, De SantisMC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med 2014;46:372-83.
5. Huang K, Fingar DC. Growing knowledge of the mTOR signaling network. Semin Cell Dev Biol 2014;36:79-90.
6. Magnuson B, Ekim B, Fingar DC. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem J 2012;441:1-21.
7. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010;17:249-61.
8. Bakan I, Laplante M. ConnectingmTORC1 signaling to SREBP-1 activation. Curr Opin Lipidol 2012;23:226-34.
9. Betz C, Hall MN. Where is mTOR and what is it doing there? J Cell Biol 2013;203:563-74.
10. Su B, Jacinto E. Mammalian TOR signaling to the AGC kinases. Crit Rev Biochem Mol Biol 2011;46:527-47.
11. Garcia-Echeverria C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment Bioorg Med Chem Lett 2010;20:4308-12.
12. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, et al. mTOR kinase inhibition causes feedbackdependent biphasic regulation of AKT signaling. Cancer Discov 2011;3: 248-59.
13. Kang SA, Pacold ME, Lim D, Lou HJ, Ottina K, Gray NS, et al. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 2013;341:364-74.
14. Van Asten K, Neven P, Lintermans A, Wildiers H, Paridaens R. Aromatase inhibitors in the breast cancer clinic: focus on exemestane. Endocr Relat Cancer 2014;21:R31-49.
15. Heel RC, Brogden RN, Speight TM, Avery GS. Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 1978;16:1-24.
16. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;15:3867-73.
17. Jerusalem G, Bachelot T, Barrios C, Neven P, Di Leo A, Janni W, et al. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer. Cancer Treat Rev 2015;41:94-104.
18. Chumsri S, Sabnis G, Tkaczuk K, Brodie A. mTOR inhibitors: changing landscape of endocrine-resistant breast cancer. Future Oncol 2014;10:443-56.
19. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
20. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATPcompetitive mammalian target of rapamycin inhibitor reveals rapamycinresistant functions of mTORC1. J Biol Chem 2009;12:8023-32.
21. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70:288-98.
22. Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, et al. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro. Breast Cancer Res 2014;16:R12.
23. Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HME, Gomez S, et al. Optimization of potent and selective dualmTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 2013;23:1212-6.
24. Miller TW, Hennessy BT, Fox EM, Mills GB, Chen H, Higham C, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-13.
25. Coser KR, Wittner BS, Rosenthal NIF, Collins S, Melas A, Smith SL, et al. Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Proc Natl Acad Sci U S A 2009;106:14536-41.
26. Bihani T, Ezell SA, Ladd B, Grosskurth SE, Mazzola AM, Pietras M, et al. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. Oncotarget 2015;6:2407-20.
27. Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation ofmonotherapy activity with genetic background. Mol Cancer Ther 2012;11:873-87.
28. Milosevic J, Klinge J, Borg AL, Foukakis T, Bergh J, Tobin NP. Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies. BMC Cancer 2013;13:473-84.
29. Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, et al. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov 2014;4:334-47.
30. Solit DB, She Y, Lobo J, Kris MG, Scher HI, Rosen N, et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Canc Res 2005;11:1983-9.
31. Bardia A. Targeting the estrogen receptor: old receptor, new drug(s). Ann Oncol 2015;26(suppl 2):ii3.
32. Patel MR, Hamilton E, LoRusso PM, Gluck WL, Jones SF, Kittaneh M, et al. A phase I study evaluating continuous and intermittent AZD2014 in combination with fulvestrant in patients with ER+ advanced metastatic breast cancer [abstract]. In: Proceedings of the AACR 106th Annual Meeting; 2015 April 18-22; Philadelphia, PA: AACR; 2015. Abstract nr CT233.